Cell and gene therapies promise to potentially transform the management of devastating and life-threatening chronic diseases for many patients. However, life sciences companies developing these innovative therapies continue to face reimbursement and patient access challenges.
From these presentation slides, you’ll learn more on:
- A summary of approved and investigational cell and gene therapies in late-stage development
- Common reimbursement and access challenges for cell and gene therapies, including payment methodologies, correct coding, and billing
- Review an inpatient case study for Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel)